Vorapaxar in the Secondary Prevention of Atherothrombotic EventsDavid A. Morrow, Sabina A. Murphy, Anthony J. Dalby et al.|New England Journal of Medicine|2012Cited by 941
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38Stephen D. Wiviott, Elliott M. Antman, Eugene Braunwald et al.|Circulation|2008Cited by 757